Appendix EExcluded Studies

Publication Details

All studies listed below were reviewed in their full-text version and excluded for the reason shown in bold. Reasons for exclusion signify only the usefulness of the articles for this study and are not intended as criticisms of the articles.

Full text not available

  1. Kostulski A, Rabe-Jablonska J. Effect of antipsychotic drugs on weight gain and metabolic disorders in schizophrenic patients.

Published prior to 1980

  1. Gallant DM, Bishop MP, Schuchs V. A clinical trial of an oral hypoglycemic agent in chronic schizophrenic patients. Curr Ther Res Clin Exp. 1963;5:628–9. [PubMed: 14084034]
  2. Harmatz MG, Lapuc P. Behavior modification of overeating in a psychiatric population. J Consult Clin Psychol. 1968;32(5):583–7. [PubMed: 5743317]
  3. Modell W, Hussar AE. Failure of dextroamphetamine sulfate to influence eating and sleeping patterns in obese schizophrenic patients: clinical and pharmacological significance. JAMA. 1965;193:275–8. [PubMed: 14310348]
  4. Sletten IW, Ognjanov V, Menendez S, et al. Weight reduction with chlorphenetermine and phenmetrazine in obese psychiatric patients during chlorpromazine therapy. Curr Ther Res Clin Exp. 1967;9(11):570–5. [PubMed: 4965506]

Non-English language

  1. Lopez-Mato A, Rovner J, Illa G, et al. [Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration]. Vertex. 2003;14(52):85–96. [PubMed: 12883589]
  2. Wang B, Du GP. Behavioural intervention for antipsychotic caused weight gain. Medical Journal of Chinese People’s Health. 2008;20(9):2117–8.

Not a full publication (abstract only)

  1. Alvarez-Jimenez M. Tackling the physical consequences of psychosis and its treatment. Early Interv Psychiatry. 2010;4:17.
  2. Firestone L, Ames D, Aragaki DLR, et al. Efficacy and safety of a lifestyle balance program for antipsychotic medication associated obesity. PM and R. 2011;3(10 SUPPL 1):S258–S259.
  3. Ganguli R, Brar JS. Behavioural intervention for weight loss in schizophrenia: An RCT with active controls. Indian Journal of Psychiatry. 2011;53(5 SUPPL 1):S44.
  4. Ginsberg DL. Add-on sibutramine for olanzapine-induced weight gain. Primary Psychiatry. 2004;11(7):24.
  5. Greil W, Gillhoff K, Emini L, et al. Effects of a multimodal lifestyle intervention on body mass index in patients with bipolar disorder-a randomized controlled trial. Int Clin Psychopharmacol. 2011;26:e2. [PMC free article: PMC3025996] [PubMed: 21274359]
  6. Lieberman J, Jarskog LF, Hamer R, et al. Metformin for obesity and metabolic abnormalities in schizophrenia. Neuropsychopharmacology. 2010;35 SUPPL 1:S225–S226.
  7. Lu RB, Lee SY. Add-on memantine to valproate treatment increase HDL in recently depressed patients with bipolar II disorder-a placebo-controlled 12-week study. Bipolar Disorders. 2012;14 SUPPL 1:99.
  8. Newcomer J, Loebel A, Pikalov A, et al. Impact of lurasidone and olanzapine on framingham ten-year coronary heart disease risk estimate in schizophrenia. Neuropsychopharmacology. 2010;35 SUPPL 1:S334–S335.
  9. Ratliff JC, Palmese LB, Tonizzo KM, et al. Pilot trial of contingency management for the treatment of antipsychotic-induced weight gain. Obesity. 2011;19 SUPPL 1:S99–S100.
  10. Scheewe T, Kroes A, Takken T, et al. Effect of cardiovascular exercise on mental and physical health in patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience. 2011;261 SUPPL 1:S97.
  11. Slavkovic V, Tosic Golubovic S, Zikic O, et al. The influence of antipsychotics on the occurrence of the metabolic syndrome in schizophrenic patients. Eur Neuropsychopharmacol. 2011;21:S474–S475.
  12. Stroup TS, Hamer RM, Ray N, et al. The effect of switching from olanzapine, quetiapine, or risperidone to aripiprazole on risk of cardiovascular disease: Results from the comparison of antipsychotics for metabolic problems (CAMP) study. Neuropsychopharmacology. 2011;36(SUPPL 1):S174.
  13. Stroup TS, Hamer RM, Ray N, et al. The effect of switching from olanzapine, quetiapine, or risperidone to aripiprazole on risk of cardiovascular disease: Results from the comparison of antipsychotics for metabolic problems (CAMP) study. Neuropsychopharmacology. 2011;36 SUPPL 1:S424–S425.
  14. Tek C, Ratliff JC, Reutenauer EL, et al. Naltrexone for antipsychotic-induced weight gain in women with schizophrenia. Biol Psychiatry. 2011;69(9):283S.
  15. Tek C, Ratliff JC, Reutenauer EL, et al. Low-dose naltrexone for antipsychotic-induced weight gain in women with schizophrenia. Obesity. 2011;19 SUPPL 1:S181.

Not original peer-reviewed research paper

  1. Baptista T, Beaulieu S. Body weight gain, insulin, and leptin in olanzapine-treated patients. J Clin Psychiatry. 2001;62(11):902–4. [PubMed: 11775052]
  2. Casagrande SS, Jerome GJ, Dalcin AT, et al. Randomized trial of achieving healthy lifestyles in psychiatric rehabilitation: the ACHIEVE trial. BMC Psychiatry. 2010;10:108. [PMC free article: PMC3016313] [PubMed: 21144025]
  3. Cohen D. Diabetes mellitus during olanzapine and quetiapine treatment in Japan. J Clin Psychiatry. 2005;66(2):265–6. author reply 266–7. [PubMed: 15705015]
  4. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry. 2000;45(2):198. [PubMed: 10742883]
  5. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res. 2006;82(1):115–117. [PubMed: 16326074]
  6. Lessig MC, Shapira NA, Murphy TK. Topiramate for reversing atypical antipsychotic weight gain. J Am Acad Child Adolesc Psychiatry. 2001;40(12):1364. [PubMed: 11765278]
  7. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry. 2002;63(11):1045. [PubMed: 12469686]
  8. Pavlovic ZM. Orlistat in the treatment of clozapine-induced hyperglycemia and weight gain. Eur Psychiatry. 2005;20(7):520. [PubMed: 16275033]
  9. Post RM, Altshuler LL, Frye MA, et al. New findings from the Bipolar Collaborative Network: clinical implications for therapeutics. Curr Psychiatry Rep. 2006;8(6):489–97. [PubMed: 17162830]
  10. Praharaj SK, Jana AK, Goyal N, et al. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol. 2011;71(3):377–82. [PMC free article: PMC3045546] [PubMed: 21284696]

Not a randomized trial of 20 or more

  1. Alptekin K, Hafez J, Brook S, et al. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol. 2009;24(5):229–38. [PubMed: 19531959]
  2. Anghelescu I, Klawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain. J Clin Psychopharmacol. 2000;20(6):716–7. [PubMed: 11106155]
  3. Arranz B, San L, Duenas RM, et al. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol. 2007;22(1):11–5. [PubMed: 17191265]
  4. Bahk WM, Lee KU, Chae JH, et al. Open label study of the effect of amantadine on weight gain induced by olanzapine. Psychiatry Clin Neurosci. 2004;58(2):163–7. [PubMed: 15009821]
  5. Baptista T, Hernandez L, Prieto LA, et al. Metformin in obesity associated with antipsychotic drug administration: a pilot study. J Clin Psychiatry. 2001;62(8):653–5. [PubMed: 11561940]
  6. Bobo WV, Jayathilake K, Lee MA, et al. Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics. Psychiatry Res. 2010;176(2–3):114–9. [PubMed: 20199813]
  7. Bradshaw T, Lovell K, Bee P, et al. The development and evaluation of a complex health education intervention for adults with a diagnosis of schizophrenia. J Psychiatr Ment Health Nurs. 2010;17(6):473–86. [PubMed: 20633074]
  8. Brown C, Goetz J, Van Sciver A, et al. A psychiatric rehabilitation approach to weight loss. Psychiatr Rehabil J. 2006;29(4):267–73. [PubMed: 16689037]
  9. Chawla B, Luxton-Andrew H. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. Hum Psychopharmacol. 2008;23(3):211–6. [PubMed: 18219624]
  10. Colombo GL, Caruggi M, Di Matteo S, et al. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat. 2008;4(5):967–76. [PMC free article: PMC2626916] [PubMed: 19183788]
  11. Cosway R, Strachan MW, Dougall A, et al. Cognitive function and information processing in type 2 diabetes. Diabet Med. 2001;18(10):803–10. [PubMed: 11678970]
  12. Faries DE, Ascher-Svanum H, Nyhuis AW, et al. Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. Curr Med Res Opin. 2008;24(5):1399–405. [PubMed: 18397549]
  13. Gupta S, Droney T, Al-Samarrai S, et al. Olanzapine: weight gain and therapeutic efficacy. J Clin Psychopharmacol. 1999;19(3):273–5. [PubMed: 10350036]
  14. Gupta S, Masand PS, Virk S, et al. Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res. 2004;70(1):57–62. [PubMed: 15246464]
  15. Heggelund J, Nilsberg GE, Hoff J, et al. Effects of high aerobic intensity training in patients with schizophrenia: a controlled trial. Nord J Psychiatry. 2011;65(4):269–75. [PMC free article: PMC3169036] [PubMed: 21332297]
  16. Henderson DC, Fan X, Copeland PM, et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol. 2009;29(2):165–9. [PMC free article: PMC4311767] [PubMed: 19512978]
  17. Henderson DC, Fan X, Copeland PM, et al. Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol. 2009;24(3):225–32. [PMC free article: PMC4327763] [PubMed: 19283774]
  18. Henderson DC, Fan X, Sharma B, et al. A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr Scand. 2009;119(6):457–65. [PMC free article: PMC4296018] [PubMed: 19183127]
  19. Idomje OB, Festus OO, Akpamu U, et al. A comparative study of the effects of clozapine and risperidone monotherapy on lipid profile in Nigerian patients with schizophrenia. International Journal of Pharmacology. 2012;8(3):170–176.
  20. Iglesias-Garcia C, Toimil-Iglesias A, Alonso-Villa MJ. Pilot study of the efficacy of an educational programme to reduce weight, on overweight and obese patients with chronic stable schizophrenia. J Psychiatr Ment Health Nurs. 2010;17(9):849–51. [PubMed: 21077409]
  21. Jean-Baptiste M, Tek C, Liskov E, et al. A pilot study of a weight management program with food provision in schizophrenia. Schizophr Res. 2007;96(1–3):198–205. [PubMed: 17628437]
  22. Karayal ON, Glue P, Bachinsky M, et al. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. J Psychiatr Pract. 2011;17(2):100–9. [PubMed: 21430488]
  23. Kim S-W, Shin I-S, Kim J-M, et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol. 2009;32(5):243–249. [PubMed: 19620849]
  24. Kline NS, Blair J, Cooper TB, et al. A controlled sevn year study of endocrine and other indices in drug treated chronic schizophrenics. Acta Psychiatr Scand Suppl. 1968;206:7–75. [PubMed: 4890732]
  25. Larmo I, de Nayer A, Windhager E, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Hum Psychopharmacol. 2005;20(8):573–81. [PubMed: 16175656]
  26. McEvoy J, Freudenreich O, McGee M, et al. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry. 1995;37(8):550–2. [PubMed: 7619979]
  27. Porsdal V, Beal C, Kleivenes OK, et al. The Scandinavian Solutions for Wellness study - a two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disorders. BMC Psychiatry. 2010;10:42. [PMC free article: PMC2898739] [PubMed: 20537122]
  28. Poulin MJ, Chaput JP, Simard V, et al. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry. 2007;41(12):980–9. [PubMed: 17999270]
  29. Sajatovic M, Dawson NV, Perzynski AT, et al. Best practices: Optimizing care for people with serious mental illness and comorbid diabetes. Psychiatr Serv. 2011;62(9):1001–3. [PMC free article: PMC4497574] [PubMed: 21885575]
  30. Sajatovic M, Dawson NV, Perzynski AT, et al. Best practices: Optimizing care for people with serious mental illness and comorbid diabetes. Psychiatr Serv. 2011;62(9):1001–3. [PMC free article: PMC4497574] [PubMed: 21885575]
  31. Sato Y, Yasui-Furukori N, Furukori H, et al. A crossover study on the glucose metabolism between treatment with olanzapine and risperidone in schizophrenic patients. Exp Clin Psychopharmacol. 2010;18(5):445–50. [PubMed: 20939648]
  32. Skouroliakou M, Giannopoulou I, Kostara C, et al. Effects of a nutritional intervention in obese postmenopausal women on atypical antipsychotics. Maturitas. 2010;67(2):166–70. [PubMed: 20605075]
  33. Skouroliakou M, Giannopoulou I, Kostara C, et al. Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine. Nutrition. 2009;25(7–8):729–35. [PubMed: 19286349]
  34. Takahashi H, Sassa T, Shibuya T, et al. Effects of sports participation on psychiatric symptoms and brain activations during sports observation in schizophrenia. Translational Psychiatry. 2012;2 [PMC free article: PMC3316153] [PubMed: 22832861]
  35. Voruganti LN, Whatham J, Bard E, et al. Going beyond: an adventure- and recreation-based group intervention promotes well-being and weight loss in schizophrenia. Can J Psychiatry. 2006;51(9):575–80. [PubMed: 17007224]
  36. Vreeland B, Minsky S, Menza M, et al. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv. 2003;54(8):1155–7. [PubMed: 12883145]
  37. Watanabe J, Suzuki Y, Sugai T, et al. The lipid profiles in Japanese patients with schizophrenia treated with antipsychotic agents. Gen Hosp Psychiatry. 2012 [PubMed: 22591814]
  38. Weber M, Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr Res. 2006;83(1):95–101. [PubMed: 16507343]

Not a study population of interest

  1. Baptista T, Uzcategui E, Rangel N, et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res. 2008;159(1–2):250–3. [PubMed: 18374423]
  2. Baptista T, Sandia I, Lacruz A, et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int Clin Psychopharmacol. 2007;22(2):69–76. [PubMed: 17293706]
  3. Baptista T, Rangel N, Fernandez V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res. 2007;93(1–3):99–108. [PubMed: 17490862]
  4. Baptista T, Martinez J, Lacruz A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry. 2006;51(3):192–6. [PubMed: 16618011]
  5. Brown S, Smith E. Can a brief health promotion intervention delivered by mental health key workers improve clients’ physical health: A randomized controlled trial. Journal of Mental Health. 2009;18(5):372–378.
  6. Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol. 2005;15(1):13–21. [PubMed: 15572269]
  7. Druss BG, von Esenwein SA, Compton MT, et al. A randomized trial of medical care management for community mental health settings: the Primary Care Access, Referral, and Evaluation (PCARE) study. Am J Psychiatry. 2010;167(2):151–9. [PMC free article: PMC3775666] [PubMed: 20008945]
  8. Joffe G, Takala P, Tchoukhine E, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69(5):706–11. [PubMed: 18426261]
  9. Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005;54(8):2404–14. [PMC free article: PMC1360738] [PubMed: 16046308]
  10. Ko YH, Joe SH, Jung IK, et al. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol. 2005;28(4):169–75. [PubMed: 16062095]
  11. Methapatara W, Srisurapanont M. Pedometer walking plus motivational interviewing program for Thai schizophrenic patients with obesity or overweight: a 12-week, randomized, controlled trial. Psychiatry Clin Neurosci. 2011;65(4):374–80. [PubMed: 21682813]
  12. Milano W, Grillo F, Del Mastro A, et al. Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study. Adv Ther. 2007;24(1):123–34. [PubMed: 17526469]
  13. Tchoukhine E, Takala P, Hakko H, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial. J Clin Psychiatry. 2011;72(3):326–30. [PubMed: 20816037]
  14. Young AS, Mintz J, Cohen AN. Using information systems to improve care for persons with schizophrenia. Psychiatr Serv. 2004;55(3):253–5. [PubMed: 15001724]

Not appropriate setting

  1. Baptista T, Rangel N, El Fakih Y, et al. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry. 2009;42(1):14–9. [PubMed: 19153941]
  2. Cordes J, Th Nker J, Regenbrecht G, et al. Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial. World J Biol Psychiatry. 2011 [PubMed: 21745127]
  3. Covell NH, Weissman EM, Essock SM. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophr Bull. 2004;30(2):229–40. [PubMed: 15279042]
  4. Del Valle MC, Loebel AD, Murray S, et al. Change in framingham risk score in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, 6-week trial of ziprasidone and olanzapine. Prim Care Companion J Clin Psychiatry. 2006;8(6):329–33. [PMC free article: PMC1764512] [PubMed: 17245453]
  5. Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry. 2004;65(6):766–71. [PubMed: 15291653]
  6. Melamed Y, Stein-Reisner O, Gelkopf M, et al. Multi-modal weight control intervention for people with persistent mental disorders. Psychiatr Rehabil J. 2008;31(3):194–200. [PubMed: 18194946]
  7. Poyurovsky M, Fuchs C, Pashinian A, et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl) 2007;192(3):441–8. [PubMed: 17310385]
  8. Poyurovsky M, Isaacs I, Fuchs C, et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry. 2003;160(2):297–302. [PubMed: 12562576]
  9. Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry. 2002;159(6):1058–60. [PubMed: 12042201]
  10. Smith RC, Rachakonda S, Dwivedi S, et al. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients. Psychiatry Research. 2012 [PubMed: 22475524]
  11. Wu MK, Wang CK, Bai YM, et al. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv. 2007;58(4):544–50. [PubMed: 17412858]
  12. Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2008;165(3):352–8. [PubMed: 18245179]

Length of followup less than 2 months

  1. Brown S, Chan K. A randomized controlled trial of a brief health promotion intervention in a population with serious mental illness. J Mental Health. 2006;15(5):543–549.
  2. Ganguli R, Brar JS, Mahmoud R, et al. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study. BMC Med. 2008;6:17. [PMC free article: PMC2474645] [PubMed: 18590519]
  3. Kingsbury SJ, Fayek M, Trufasiu D, et al. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry. 2001;62(5):347–9. [PubMed: 11411816]

No interventions of interest

  1. Afshar H, Roohafza H, Mousavi G, et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol. 2009;23(2):157–62. [PubMed: 18515465]
  2. Archie S, Wilson JH, Osborne S, et al. Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients. Can J Psychiatry. 2003;48(9):628–32. [PubMed: 14631884]
  3. Basu R, Thimmaiah TG, Chawla JM, et al. Changes in metabolic syndrome parameters in patients with schizoaffective disorder who participated in a randomized, placebo-controlled trial of topiramate. Asian J Psychiatr. 2009;2(3):106–111. [PubMed: 23051050]
  4. Bobo WV, Epstein RA Jr, Shelton RC. Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: a randomized, open comparison in outpatients with bipolar depression. Ann Clin Psychiatry. 2011;23(3):193–201. [PubMed: 21808751]
  5. Bowden CL, Calabrese JR, Ketter TA, et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry. 2006;163(7):1199–201. [PubMed: 16816224]
  6. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166(4):391–9. [PubMed: 12610718]
  7. Emsley R, Turner HJ, Schronen J, et al. Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. Int J Neuropsychopharmacol. 2005;8(2):175–82. [PubMed: 15737251]
  8. Essock SM, Schooler NR, Stroup TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011;168(7):702–8. [PMC free article: PMC3739691] [PubMed: 21536693]
  9. Goodall E, Oxtoby C, Richards R, et al. A clinical trial of the efficacy and acceptability of {d}-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry. 1988;153:208–213. [PubMed: 2908235]
  10. Henderson DC, Copeland PM, Daley TB, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry. 2005;162(5):954–62. [PubMed: 15863798]
  11. Henderson DC, Fan X, Copeland PM, et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand. 2007;115(2):101–5. [PubMed: 17244173]
  12. Henderson DC, Freudenreich O, Borba CP, et al. Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophr Res. 2011;130(1–3):53–6. [PubMed: 21565464]
  13. Kemp DE, Calabrese JR, Tran QV, et al. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010;71(9):1138–44. [PMC free article: PMC3590811] [PubMed: 20492838]
  14. Kemp DE, Karayal ON, Calabrese JR, et al. Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: Long-term changes in weight and metabolic profiles. Eur Neuropsychopharmacol. 2011 [PMC free article: PMC3225596] [PubMed: 21798721]
  15. Kinon BJ, Basson BR, Gilmore JA, et al. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry. 2000;61(11):833–40. [PubMed: 11105736]
  16. Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010;35(2):581–90. [PMC free article: PMC3055392] [PubMed: 19890258]
  17. Kinon BJ, Liu-Seifert H, Ahl J, et al. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study. Ann N Y Acad Sci. 2004;1032:295–6. [PubMed: 15677433]
  18. Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28(4):392–400. [PubMed: 18626265]
  19. Kolotkin RL, Corey-Lisle PK, Crosby RD, et al. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. Eur Psychiatry. 2008;23(8):561–6. [PubMed: 18374544]
  20. Kusumi I, Honda M, Uemura K, et al. Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: a randomized open-label trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011 [PubMed: 22119746]
  21. McCreadie RG, Kelly C, Connolly M, et al. Dietary improvement in people with schizophrenia: randomised controlled trial. Br J Psychiatry. 2005;187:346–51. [PubMed: 16199794]
  22. McElroy SL, Frye MA, Altshuler LL, et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord. 2007;9(4):426–34. [PubMed: 17547588]
  23. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. 2002;4(3):207–13. [PubMed: 12180276]
  24. McIntyre RS, McElroy SL, Eudicone JM, et al. A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder. Primary Care Companion to the Journal of Clinical Psychiatry. 2011;13(6) [PMC free article: PMC3304683] [PubMed: 22454801]
  25. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004;65 Suppl 18:47–56. [PubMed: 15600384]
  26. Meltzer HY, Bonaccorso S, Bobo WV, et al. A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: Influence of valproic acid augmentation. Journal of Clinical Psychiatry. 2011;72(12):1602–1610. [PubMed: 21813074]
  27. Newcomer JW, Meyer JM, Baker RA, et al. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophr Res. 2008;106(2–3):300–7. [PMC free article: PMC3769700] [PubMed: 18973991]
  28. Rosenheck RA, Davis S, Covell N, et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res. 2009;107(1):22–9. [PubMed: 18993031]
  29. Roy Chengappa K, Kupfer DJ, Parepally H, et al. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Bipolar Disord. 2007;9(6):609–17. [PubMed: 17845276]
  30. Roy Chengappa KN, Schwarzman LK, Hulihan JF, et al. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J Clin Psychiatry. 2006;67(11):1698–706. [PubMed: 17196048]
  31. Schreiner A, Niehaus D, Shuriquie NA, et al. Metabolic Effects of Paliperidone Extended Release Versus Oral Olanzapine in Patients With Schizophrenia: A Prospective, Randomized, Controlled Trial. J Clin Psychopharmacol. 2012;32(4):449–457. [PubMed: 22722501]
  32. Xiang YT, Wang CY, Ungvari GS, et al. Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia. Pharmacopsychiatry. 2011;44(4):135–41. [PubMed: 21710403]

No outcomes of interest

  1. Acil AA, Dogan S, Dogan O. The effects of physical exercises to mental state and quality of life in patients with schizophrenia. J Psychiatr Ment Health Nurs. 2008;15(10):808–15. [PubMed: 19012672]
  2. Chafetz L, White M, Collins-Bride G, et al. Clinical trial of wellness training: health promotion for severely mentally ill adults. J Nerv Ment Dis. 2008;196(6):475–83. [PubMed: 18552625]
  3. Goodrich DE, Kilbourne AM, Lai Z, et al. Design and rationale of a randomized controlled trial to reduce cardiovascular disease risk for patients with bipolar disorder. Contemp Clin Trials. 2012;33(4):666–78. [PubMed: 22386799]
  4. Jerome GJ, Dalcin AT, Young DR, et al. Rationale, design and baseline data for the Activating Consumers to Exercise through Peer Support (ACE trial): A randomized controlled trial to increase fitness among adults with mental illness. Mental Health and Physical Activity. 2012 [PMC free article: PMC3587110] [PubMed: 23471190]
  5. Kilbourne AM, Post EP, Nossek A, et al. Improving medical and psychiatric outcomes among individuals with bipolar disorder: a randomized controlled trial. Psychiatr Serv. 2008;59(7):760–8. [PubMed: 18586993]
  6. Kim SW, Chung YC, Lee YH, et al. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. Int Clin Psychopharmacol. 2012 [PubMed: 22809972]
  7. Muscatello MR, Bruno A, Pandolfo G, et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol. 2011;25(5):667–74. [PubMed: 20615930]
  8. Scheewe TW, Takken T, Kahn RS, et al. Effects of Exercise Therapy on Cardiorespiratory Fitness in Schizophrenia Patients. Med Sci Sports Exerc. 2012 [PubMed: 22525773]